Biomarine is an American biotechnology company focused on enzyme replacement therapy.
On August 1, it reported financial results for the second quarter of 2019. Revenue for the quarter was $ 387.8 million, up 4% from $ 372.8 million for the same period last year. The net loss was $ 37.4 million, compared to a net loss of $ 16.8 million in the same quarter last year.
Other points to consider:
All of the above, of course, at your own discretion, your trading rules and your preferred trading strategies.
This is not a recommendation to buy / sell.